An interventional study of Care Coordinator Model in Psoriasis, Psoriatic Arthritis and Psoriatic Conditions, sponsored by University of Pennsylvania. Completed at 20 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 27th largest by enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2023, is one of 20 with no phase, and was the 157th registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 603 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 228 across the 159 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 194 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 8 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
17 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 17 to your calendar (.ics) → With an account.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
This study's enrollment of 603 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Care Coordinator Model
A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
Change in LDL
Change in LDL cholesterol
Time frame: 6 months
Addition of new medication
Percent newly using lipid lowering, hypertension (HTN), or diabetes (DM) medications
Time frame: 6 months
Change in 10-year cardiovascular (CV) risk
Change in predicted 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among patients with baseline 10-year risk greater than or equal to 5% measured by the American College of Cardiology ASCVD risk estimator tool for predicting percent risk for atherosclerotic cardiovascular disease.
Time frame: 6 months
30% LDL reduction
Percent with 7.5% to 20% risk who achieve a 30% or greater reduction in LDL on follow up testing
Time frame: 6 months
50% LDL reduction
Percent with greater than or equal to 20% risk who achieve LDL reduction of greater than or equal to 50%
Time frame: 6 months
LDL reduction under 100
Percent who achieve LDL less than 100 mg/dL or non-HDL less than 130 mg/dL
Time frame: 6 months
Change in blood pressure
Change in systolic blood pressure (mm Hg)
Time frame: 6 months
Change in cholesterol
Change in total cholesterol (mg/dL)
Time frame: 6 months
Change in HDL
Change in HDL cholesterol (mg/dL)
Time frame: 6 months
Change in non-HDL
Change in non-HDL cholesterol (mg/dL)
Time frame: 6 months
Change in HbA1c
Change in hemoglobin A1c level measured in percent.
Time frame: 6 months
Change in Weight
Change in weight calculated by BMI (kg/m2)
Time frame: 6 months
Smoking status change
Percent of patients who quit smoking measured by self-reported response to survey question.
Time frame: 6 months
Percent undergoing additional CV testing
Percent undergoing additional cardiovascular (CV) risk testing such as stress test, coronary calcium score or related imaging.
Time frame: 6 months
Change in Body Surface Area (BSA) psoriasis severity
Change in percent of body surface area affected by psoriasis will be assessed.
Time frame: 6 months
Change in Physicians Global Assessment (PGA) psoriasis severity
Change in PGA score measured from 0-5 with 5 being the most severe psoriasis and 0 being the least severe.
Time frame: 6 months
Change in dermatology life quality index (DLQI)
Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: 6 months
Change in general health
EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.
Time frame: 6 months
Change in reported psoriasis medication use
Proportion of patients who have reported any change in medications taken for psoriatic disease measured through a patient reported survey.
Time frame: 6 months
Change in physical activity days active
Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the number of days active for at least 30 minutes over the past month
Time frame: 6 months
Change in physical activity level
Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the patient reported level of physical activity on a likert scale from seldom active to vigorously active.
Time frame: 6 months
Patient experience with Care Coordinator Model
Patient experience with the care coordinator will be measured through the Patient Experience Survey with a likert scale from strongly agree to strongly disagree.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Sep 2026, 38 months.
Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's 38 months is above that.
Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.